StocksMedium•5 October 2026•
1 min read
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment
Key Facts
1HeartBeam has received the FDA Breakthrough Device Designation for its technology designed for heart attack assessment.
HeartBeam has received the FDA Breakthrough Device Designation for its technology designed for heart attack assessment. Business Wire reported that the designation is intended to expedite the development and regulatory review of devices that provide for more effective diagnosis of life-threatening conditions.
BEAT closed at $0.4346 on October 2, 2026, with a session high of $0.454 and a low of $0.4218. This regulatory milestone comes as the company focuses on advancing its medical device technology for critical cardiac care.